PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy

Abstract Clinicopathological prognostic features have limited value to identify with precision newly diagnosed patients with hormone receptor (HR)-positive, HER2-negative breast cancer (BC), who would benefit from chemotherapy (CT) in addition to adjuvant hormonal therapy (HT). The 21-gene Oncotype...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Francesco Cognetti, Riccardo Masetti, Alessandra Fabi, Giulia Bianchi, Donatella Santini, Alessia Rognone, Giovanna Catania, Domenico Angelucci, Giuseppe Naso, Mario Giuliano, Lucia Vassalli, Patrizia Vici, Giovanni Scognamiglio, Daniele Generali, Alberto Zambelli, Marco Colleoni, Corrado Tinterri, Francesco Scanzi, Leonardo Vigna, Paola Scavina, Teresa Gamucci, Emilia Marrazzo, Angelo Fedele Scinto, Rossana Berardi, Maria Agnese Fabbri, Graziella Pinotti, Daniela Franco, Daniela Andreina Terribile, Giuseppe Tonini, Daniela Cianniello, Sandro Barni
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/a0a882fd09a64018b374c4f2f70cd885
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a0a882fd09a64018b374c4f2f70cd885
record_format	dspace
spelling	oai:doaj.org-article:a0a882fd09a64018b374c4f2f70cd8852021-12-02T14:41:54ZPONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy10.1038/s41523-021-00246-42374-4677https://doaj.org/article/a0a882fd09a64018b374c4f2f70cd8852021-05-01T00:00:00Zhttps://doi.org/10.1038/s41523-021-00246-4https://doaj.org/toc/2374-4677Abstract Clinicopathological prognostic features have limited value to identify with precision newly diagnosed patients with hormone receptor (HR)-positive, HER2-negative breast cancer (BC), who would benefit from chemotherapy (CT) in addition to adjuvant hormonal therapy (HT). The 21-gene Oncotype DX Breast Recurrence Score® (RS) assay has been demonstrated to predict CT benefit, hence supporting personalized decisions on adjuvant CT. The multicenter, prospective, observational study PONDx investigated the real-life use of RS® results in Italy and its impact on treatment decisions. Physicians’ treatment recommendations (HT ± CT) were documented before and after availability of RS results, and changes in recommendations were determined. In the HR+ HER2− early BC population studied (N = 1738), physicians recommended CT + HT in 49% of patients pre-RS. RS-guided treatment decisions resulted in 36% reduction of CT recommendations. PONDx confirms that RS results provide clinically relevant information for CT recommendation in early-stage BC, resulting in a reduction of more than a third of CT use.Francesco CognettiRiccardo MasettiAlessandra FabiGiulia BianchiDonatella SantiniAlessia RognoneGiovanna CataniaDomenico AngelucciGiuseppe NasoMario GiulianoLucia VassalliPatrizia ViciGiovanni ScognamiglioDaniele GeneraliAlberto ZambelliMarco ColleoniCorrado TinterriFrancesco ScanziLeonardo VignaPaola ScavinaTeresa GamucciEmilia MarrazzoAngelo Fedele ScintoRossana BerardiMaria Agnese FabbriGraziella PinottiDaniela FrancoDaniela Andreina TerribileGiuseppe ToniniDaniela CiannielloSandro BarniNature PortfolioarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Breast Cancer, Vol 7, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Francesco Cognetti Riccardo Masetti Alessandra Fabi Giulia Bianchi Donatella Santini Alessia Rognone Giovanna Catania Domenico Angelucci Giuseppe Naso Mario Giuliano Lucia Vassalli Patrizia Vici Giovanni Scognamiglio Daniele Generali Alberto Zambelli Marco Colleoni Corrado Tinterri Francesco Scanzi Leonardo Vigna Paola Scavina Teresa Gamucci Emilia Marrazzo Angelo Fedele Scinto Rossana Berardi Maria Agnese Fabbri Graziella Pinotti Daniela Franco Daniela Andreina Terribile Giuseppe Tonini Daniela Cianniello Sandro Barni PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy
description	Abstract Clinicopathological prognostic features have limited value to identify with precision newly diagnosed patients with hormone receptor (HR)-positive, HER2-negative breast cancer (BC), who would benefit from chemotherapy (CT) in addition to adjuvant hormonal therapy (HT). The 21-gene Oncotype DX Breast Recurrence Score® (RS) assay has been demonstrated to predict CT benefit, hence supporting personalized decisions on adjuvant CT. The multicenter, prospective, observational study PONDx investigated the real-life use of RS® results in Italy and its impact on treatment decisions. Physicians’ treatment recommendations (HT ± CT) were documented before and after availability of RS results, and changes in recommendations were determined. In the HR+ HER2− early BC population studied (N = 1738), physicians recommended CT + HT in 49% of patients pre-RS. RS-guided treatment decisions resulted in 36% reduction of CT recommendations. PONDx confirms that RS results provide clinically relevant information for CT recommendation in early-stage BC, resulting in a reduction of more than a third of CT use.
format	article
author	Francesco Cognetti Riccardo Masetti Alessandra Fabi Giulia Bianchi Donatella Santini Alessia Rognone Giovanna Catania Domenico Angelucci Giuseppe Naso Mario Giuliano Lucia Vassalli Patrizia Vici Giovanni Scognamiglio Daniele Generali Alberto Zambelli Marco Colleoni Corrado Tinterri Francesco Scanzi Leonardo Vigna Paola Scavina Teresa Gamucci Emilia Marrazzo Angelo Fedele Scinto Rossana Berardi Maria Agnese Fabbri Graziella Pinotti Daniela Franco Daniela Andreina Terribile Giuseppe Tonini Daniela Cianniello Sandro Barni
author_facet	Francesco Cognetti Riccardo Masetti Alessandra Fabi Giulia Bianchi Donatella Santini Alessia Rognone Giovanna Catania Domenico Angelucci Giuseppe Naso Mario Giuliano Lucia Vassalli Patrizia Vici Giovanni Scognamiglio Daniele Generali Alberto Zambelli Marco Colleoni Corrado Tinterri Francesco Scanzi Leonardo Vigna Paola Scavina Teresa Gamucci Emilia Marrazzo Angelo Fedele Scinto Rossana Berardi Maria Agnese Fabbri Graziella Pinotti Daniela Franco Daniela Andreina Terribile Giuseppe Tonini Daniela Cianniello Sandro Barni
author_sort	Francesco Cognetti
title	PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy
title_short	PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy
title_full	PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy
title_fullStr	PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy
title_full_unstemmed	PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy
title_sort	pondx: real-life utilization and decision impact of the 21-gene assay on clinical practice in italy
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/a0a882fd09a64018b374c4f2f70cd885
work_keys_str_mv	AT francescocognetti pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly AT riccardomasetti pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly AT alessandrafabi pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly AT giuliabianchi pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly AT donatellasantini pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly AT alessiarognone pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly AT giovannacatania pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly AT domenicoangelucci pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly AT giuseppenaso pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly AT mariogiuliano pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly AT luciavassalli pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly AT patriziavici pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly AT giovanniscognamiglio pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly AT danielegenerali pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly AT albertozambelli pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly AT marcocolleoni pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly AT corradotinterri pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly AT francescoscanzi pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly AT leonardovigna pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly AT paolascavina pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly AT teresagamucci pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly AT emiliamarrazzo pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly AT angelofedelescinto pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly AT rossanaberardi pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly AT mariaagnesefabbri pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly AT graziellapinotti pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly AT danielafranco pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly AT danielaandreinaterribile pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly AT giuseppetonini pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly AT danielacianniello pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly AT sandrobarni pondxreallifeutilizationanddecisionimpactofthe21geneassayonclinicalpracticeinitaly
_version_	1718389887312330752

PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy

Ejemplares similares